Hepatocyte growth factor prevents peritoneal fibrosis in an animal model of encapsulating peritoneal sclerosis

Journal of Nephrology

Volumn 21, Issue 1, 2008, Pages 64-73

  Matsuoka, Toshiaki ^a   Maeda, Yasuhiro ^a   Matsuo, Koki ^a   Naiki, Yoshito ^a   Tamai, Yoshihisa ^a   Sakaguchi, Mika ^a   Hasegawa, Hirofumi ^a   Funauchi, Masanori ^a   Kanamaru, Akihisa ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Continuous ambulatory peritoneal dialysis; Hepatocyte growth factor; Peritoneal mesothelial cell; Peritoneal sclerosis; Transforming growth factor beta1; Ultrafiltration capacity

Indexed keywords

CHLORHEXIDINE GLUCONATE; COMPLEMENTARY DNA; SCATTER FACTOR; CHLORHEXIDINE; DRUG DERIVATIVE; HGF PROTEIN, HUMAN;

ABDOMINAL DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CELL BASED GENE THERAPY; CONTROLLED STUDY; ENCAPSULATING PERITONEAL SCLEROSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; GENETIC TRANSFECTION; HISTOPATHOLOGY; MALE; MESOTHELIUM CELL; MICROSCOPY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PERITONEAL FIBROSIS; PERITONEUM CELL; PROTEIN SYNTHESIS; RAT; ULTRAFILTRATION; WISTAR RAT; ANIMAL; DISEASE MODEL; FIBROSIS; HUMAN; PATHOLOGY; PERITONEUM; PHYSIOLOGY; SCLEROSIS;

ANIMALS; CHLORHEXIDINE; DISEASE MODELS, ANIMAL; FIBROSIS; HEPATOCYTE GROWTH FACTOR; HUMANS; MALE; PERITONEUM; RATS; RATS, WISTAR; SCLEROSIS; TRANSFECTION; ULTRAFILTRATION;

EID: 43249115661     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Davies SJ, Phillips L, Griffiths AM, et al. What really happens to people on long-term peritoneal dialysis? Kidney Int. 1998;54:2207-2217.
2. Honda K, Nitta K, Horita S, Yumura W, Nihei H. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron. 1996;72:171-176.
3. Mateijsen MA, van der Wal AC, Hendriks PM, et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int. 1999;19:517-525.
4. Coles GA, Topley N. Long-term peritoneal membrane changes. Adv Ren Replace Ther. 2000;7:289-301.
5. Williams JD, Craig KJ, Topley N, et al. Peritoneal Biopsy Study Group. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol. 2002;13:470-479.
6. Davies SJ, Phillips L, Naish PF, Russell GI. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol. 2001;12:1046-1051.
7. Medcalf JF, Walls J, Pawluczyk IZ, Harris KP. Effects of glucose dialysate on extracellular matrix production by human peritoneal mesothelial cells (HPMC): the role of TGF-beta. Nephrol Dial Transplant. 2001;16:1885-1892.
8. Fischereder M, Schroppel B, Wiese P, et al. Regulation of glucose transporters in human peritoneal mesothelial cells. J Nephrol. 2003;16:103-109.
9. Shao JC, Yorioka N, Nishida Y, Yamakido M. Effect of pH and glucose on cultured human peritoneal mesothelial cells. Scand J Urol Nephrol. 1999;33:248-256.
10. Honda K, Nitta K, Horita S, et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant. 1999;14:1541-1549.
11. Nakamura S, Niwa T. Advanced glycation end-products and peritoneal sclerosis. Semin Nephrol. 2004;24:502-505.
12. Rampino T, Cancarini G, Gregorini M, et al. Hepatocyte growth factor/ scatter factor released during peritonitis is active on mesothelial cells. Am J Pathol. 2001;159:1275-1285.
13. Rocco MV, Chen Y, Goldfarb S, Ziyadeh FN. Elevated glucose stimulates TGF-beta gene expression and bioactivity in proximal tubule. Kidney Int. 1992;41:107-114.
14. Ko SH, Hong OK, Kim JW, et al. High glucose increases extracellular matrix production in pancreatic stellate cells by activating the renin-angiotensin system. J Cell Biochem. 2006;98:343-355.
15. Kobayashi T, Inoue T, Okada H, et al. Connective tissue growth factor mediates the profibrotic effects of transforming growth factor-beta produced by tubular epithelial cells in response to high glucose. Clin Exp Nephrol. 2005;9:114-121.
16. Roberts AB, McCune BK, Sporn MB. TGF-beta: regulation of extracellular matrix. Kidney Int. 1992;41:557-659.
17. Duncan MR, Frazier KS, Abramson S, et al. Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP. FASEB J. 1999;13:1774-1786.
18. Bonniaud P, Margetts PJ, Ask K, Flanders K, Gauldie J, Kolb M. TGF-beta and Smad3 signaling link inflammation to chronic fibrogenesis. J Immunol. 2005;175:5390-5395.
19. Fedulov AV, Ses TP, Gavrisheva NA, et al. Serum TGF-beta 1 and TNF-alpha levels and cardiac fibrosis in experimental chronic renal failure. Immunol Invest. 2005;34:143-152.
20. Czaja MJ, Weiner FR, Flanders KC, et al. In vitro and in vivo association of transforming growth factor-beta 1 with hepatic fibrosis. J Cell Biol. 1989;108:2477-2482.
21. Mizuno S, Matsumoto K, Kurosawa T, Mizuno-Horikawa Y, Nakamura T. Reciprocal balance of hepatocyte growth factor and transforming growth factor-beta 1 in renal fibrosis in mice. Kidney Int. 2000;57:937-948.
22. Mizuno S, Matsumoto K, Nakamura T. Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy. Kidney Int. 2001;59:1304-1314.
23. Matsumoto K, Nakamura T. Renotropic role and therapeutic potential of HGF in the kidney. Nephrol Dial Transplant. 2002;9:59-61.
24. Matsumoto K, Nakamura T. Hepatocyte growth factor (HGF) as a tissue organizer for organogenesis and regeneration. Biochem Biophys Res Commun. 1997;239:639-644.
25. Stella MC, Comoglio PM. HGF: a multifunctional growth factor controlling cell scattering. Int J Biochem Cell Biol. 1999;31:1357-1362.
26. Kusumoto K, Ido A, Moriuchi A, et al. Repeated intravenous injection of recombinant human hepatocyte growth factor ameliorates liver cirrhosis but causes albuminuria in rats. Int J Mol Med. 2006;17:503-509.
27. Dohi M, Hasegawa T, Yamamoto K, Marshall BC. Hepatocyte growth factor attenuates collagen accumulation in a murine model of pulmonary fibrosis. Am J Respir Crit Care Med. 2000;162:2302-2307.
28. Taniyama Y, Morishita R, Aoki M, et al. Angiogenesis and antifibrotic action by hepatocyte growth factor in cardiomyopathy. Hypertension. 2002;40:47-53.
29. Kagawa T, Takemura G, Kosai K, et al. Hepatocyte growth factor gene therapy slows down the progression of diabetic nephropathy in db/db mice. Nephron Physiol. 2006;102:92-102.
30. Matsuo K, Maeda Y, Naiki Y, et al. Possible effects of hepatocyte growth factor for the prevention of peritoneal fibrosis. Nephron Exp Nephrol. 2005;99:87-94.
31. Hjelle JT, Golinska BT, Waters DC, Steidley KR, McCarroll DR, Dobbie JW. Isolation and propagation in vitro of peritoneal mesothelial cells. Perit Dial Int. 1989;9:341-347.
32. Nakamura T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989;342:440-443.
33. Tsuboniwa N, Morishita R, Hirano T, et al. Safety evaluation of hemagglutinating virus of Japan: artificial viral envelope liposomes in nonhuman primates. Hum Gene Ther. 2001;12:469-487.
34. Yo Y, Morishita R, Nakamura S, et al. Potential role of hepatocyte growth factor in the maintenance of renal structure: anti-apoptotic action of HGF on epithelial cells. Kidney Int. 1998;54:1128-1138.
35. Mizui M, Isaka Y, Takabatake Y, et al. Electroporation-mediated HGF gene transfer ameliorated cyclosporine nephrotoxicity. Kidney Int. 2004;65:2041-2053.
36. Kirby TO, Rivera A, Rein D, et al. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin Cancer Res. 2004;10:8697-8703.
37. Anderson DG, Peng W, Akinc A, et al. A polymer library approach to suicide gene therapy for cancer. Proc Natl Acad Sci U S A. 2004;101:16028-16033.
38. Io H, Hamada C, Ro Y, Ito Y, Hirahara I, Tomino Y. Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int. 2004;65:1927-1936.
39. Naiki Y, Matsuo K, Matsuoka T, Maeda Y. Possible role of hepatocyte growth factor in regeneration of human peritoneal mesothelial cells. Int J Artif Organs. 2005;28:141-149.
40. Medcalf JF, Walls J, Pawluczyk IZ, Harris KP. Effects of glucose dialysate on extracellular matrix production by human peritoneal mesothelial cells (HPMC): the role of TGF-beta. Nephrol Dial Transplant. 2001;16:1885-1892.
41. Naiki Y, Maeda Y, Matsuo K, et al. Involvement of TGF-beta signal for peritoneal sclerosing in continuous ambulatory peritoneal dialysis. J Nephrol. 2003;16:95-102.
42. Ho-dac-Pannekeet MM, Atasever B, Struijk DG, Krediet RT. Analysis of ultrafiltration failure in peritoneal dialysis patients by means of standard peritoneal permeability analysis. Perit Dial Int. 1997;17:144-150.
43. Rippe B, Rosengren BI, Venturoli D. The peritoneal microcirculation in peritoneal dialysis. Microcirculation. 2001;8:303-320.
44. Rippe B, Venturoli D, Simonsen O, de Arteaga J. Fluid and electrolyte transport across the peritoneal membrane during CAPD according to the three-pore model. Perit Dial Int. 2004;24:10-27.
45. Heimburger O, Waniewski J, Werynski A, Tranaeus A, Lindholm B. Peritoneal transport in CAPD patients with permanent oss of ultrafiltration capacity. Kidney Int. 1990;38:495-506.
46. Wideroe TE, Smeby LC, Mjaland S, Dahl K, Berg KJ, Wessel Ass T. Long-term changes in transperitoneal water transport during continuous ambulatory peritoneal dialysis. Nephron. 1984;38:238-247.
47. Slingeneyer A, Canaud B, Mion C. Permanent loss of ultrafiltration capacity of peritoneum in long-term peritoneal dialysis. Nephron. 1983;33:133-138.
48. Smit W, van den Berg N, Schouten N, Aikens E, Struijk DG, Krediet RT. Free-water transport in fast transport status: a comparison between CAPD peritonitis and long-term PD. Kidney Int. 2004;65:298-303.
49. Ueki T, Kaneda Y, Tsutsui H, et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med. 1999;5:226-230.
50. Ozawa S, Uchiyama K, Nakamori M, et al. Combination gene therapy of HGF and truncated type II TGF-beta receptor for rat liver cirrhosis after partial hepatectomy. Surgery. 2006;139:563-573.
51. Ono M, Sawa Y, Matsumoto K, Nakamura T, Kaneda Y, Matsuda H. In vivo gene transfection with hepatocyte growth factor via the pulmonary artery induces angiogenesis in the rat lung. Circulation. 2002;106:1264-1269.
52. Nakamura S, Niwa T. Pyridoxal phosphate and hepatocyte growth factor prevent dialysate-induced peritoneal damage. J Am Soc Nephrol. 2005;16:144-150.
53. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000;6801:242-248.
54. Io H, Hamada C, Ro Y, Ito Y, Hirahara I, Tomino Y. Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int. 2004;5:1927-1936.